公司代码：600161 公司简称：天坛生物 2019 年年度报告 北京天坛生物制品股份有限公司 2019 年年度报告 1/210 2019 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人（会计主管人员）朱振海声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 考虑项目资金需求及公司实际情况和长期持续发展的需要，公司拟以 2019 年末总股本 1,045,366,807 股为基数，向全体股东每 10 股派发现金股利 0.6 元（含税），分红总金额 62,722,008.42 元（含税），留存未分配利润主要用于弥补资金缺口。同时，向全体股东每 10 股 送红股 2 股，上述送股完成后，公司总股本为 1,254,440,168 股。 六、 前瞻性陈述 ...

Financial Performance - Operating income for the period from January to September was ¥2,519,395,695.33, representing a 22.50% increase compared to the same period last year[6]. - Net profit attributable to shareholders of the listed company for the same period was ¥466,879,051.84, up 17.72% year-on-year[6]. - Basic earnings per share for the period was ¥0.45, reflecting a growth of 17.72% compared to ¥0.38 in the previous year[7]. - The weighted average return on equity increased by 2.60 percentage points to 13.02%[7]. - The company reported a net profit of ¥112,503.98, a significant increase compared to the previous period[58]. - Total operating revenue for Q3 2019 reached ¥959,057,389.27, an increase of 14.7% compared to ¥836,299,227.40 in Q3 2018[74]. - Net profit for Q3 2019 was ¥252,129,513.96, representing a 12.1% increase from ¥224,838,807.86 in Q3 2018[75]. - The company reported a total profit of ¥303,268,340.82 for Q3 2019, up from ¥272,938,606.82 in Q3 2018[75]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,193,868,182.21, an increase of 22.24% compared to the end of the previous year[6]. - Total liabilities increased to ¥1,208,074,325.61, up from ¥720,187,062.70, representing a growth of 67.6% year-over-year[23]. - The company’s total current assets decreased to ¥1,009,394,882.22 from ¥1,070,030,074.19, a decline of 5.7%[25]. - The company’s total non-current liabilities increased to ¥482,802,945.47 from ¥237,781,811.87, representing a growth of approximately 102.6%[23]. - The company’s long-term assets totaled ¥2,020,774,007.77, an increase from ¥1,634,086,176.11, reflecting ongoing investments in long-term projects[22]. - The total current liabilities amounted to ¥16,391,954.44, up from ¥3,259,519.37, representing a significant increase of 403.5%[26]. Cash Flow - The net cash flow from operating activities for the first nine months was ¥697,313,641.83, an increase of 18.78% compared to the previous year[6]. - The company reported a decrease of 85.09% in cash received from operating activities, totaling ¥98,800,669.45 compared to ¥662,767,424.51 in the previous year[16]. - The net cash flow from investing activities was -¥398,248,161.21, primarily due to increased investments in the Yong'an Blood Products project[18]. - The cash flow from financing activities showed a net inflow of ¥92,667,907.89, a turnaround from the previous period's outflow of ¥1,152,586,812.12, mainly due to the absence of significant debt repayments[18]. - The net increase in cash and cash equivalents for the first nine months of 2019 was ¥313.65 million, contrasting with a decrease of ¥952.19 million in the same period of 2018, indicating a turnaround in cash management[84]. Shareholder Information - The total number of shareholders at the end of the reporting period was 28,956[10]. - The largest shareholder, China National Biological Technology Group Corporation, held 49.96% of the shares[10]. - The top ten shareholders collectively hold 60.07% of the total shares, indicating a concentrated ownership structure[56]. Research and Development - Research and development expenses increased by 65.65% to ¥81,897,552.36 from ¥49,439,535.74, reflecting enhanced R&D efforts[15]. - Research and development expenses for Q3 2019 totaled ¥43,676,538.22, a significant increase of 104.5% from ¥21,387,266.00 in Q3 2018[28]. - The company has capitalized research and development expenditures amounting to ¥30,407,394.81, indicating ongoing investment in innovation[59]. Government Subsidies and Other Income - The company received government subsidies totaling ¥2,239,557.66 for the period from January to September[8]. - Other income rose by 158.17% to ¥2,693,455.92 from ¥1,043,307.03, mainly from increased government grants[15]. Market Strategy and Future Plans - The company plans to continue investing in new technologies and market expansion strategies to enhance its competitive position[30]. - The company plans to expand its market presence and enhance product offerings through strategic investments and partnerships[58].

公司代码：600161 公司简称：天坛生物 北京天坛生物制品股份有限公司 2019 年半年度报告 2019 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 未出席董事职务 未出席董事姓名 未出席董事的原因说明 被委托人姓名 独立董事 张连起 因公务 沈建国 三、 本半年度报告未经审计。 四、 公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人（会计主管人员）朱振海声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 重大风险提示 详见"第四节 经营情况的讨论与分析""二、其他披露事项""（二）可能面对的风险" 十、 其 ...

2018 年年度报告 公司代码：600161 公司简称：天坛生物 北京天坛生物制品股份有限公司 2018 年年度报告 1/190 2018 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | --- | --- | --- | --- | |----------------|----------------|----------------------|--------------| | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | 董事 | 吴永林 | 因公务 | 杨晓明 | 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人付道兴、主管会计工作负责人张翼及会计机构负责人（会计主管人员）朱振海声 明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 公司控股子公司成都蓉生药业有限责任公司永安血制项目处于建设期，考虑项目资金需求及 公司实际 ...

Financial Performance - Operating income increased by 27.68% to CNY 2,056,588,402.44 for the period from January to September[7] - Net profit attributable to shareholders decreased by 60.39% to CNY 396,596,229.98 for the period from January to September[7] - Basic earnings per share decreased by 60.39% to CNY 0.46 for the period from January to September[8] - Net profit decreased by 49.96% to ¥568,203,662.08, attributed to the absence of equity gains from the previous year and increased profits from blood products[19] - Total profit decreased by 44.45% to ¥692,228,100.01, mainly due to the lack of equity gains from previous year transactions[18] - The net profit for Q3 2018 was 224,838,807.86 RMB, an increase from 173,574,325.67 RMB in the same period last year, representing a growth of approximately 29.5%[31] - The total profit for Q3 2018 reached 272,938,606.82 RMB, compared to 202,052,565.79 RMB in Q3 2017, indicating a year-over-year increase of about 35%[31] - The operating profit for Q3 2018 was 274,038,499.56 RMB, up from 202,084,610.77 RMB in Q3 2017, reflecting a growth of approximately 35.6%[31] - The total revenue for the first nine months of 2018 was 1,139,628,350.83 RMB, compared to 920,101,941.75 RMB in the same period last year, indicating a year-over-year increase of approximately 23.9%[35] Cash Flow - Cash flow from operating activities increased significantly to CNY 587,081,583.71, compared to a negative cash flow of CNY 41,762,078.34 in the same period last year[7] - Net cash flow from operating activities turned positive at CNY 587,081,583.71, a significant increase of 1,505.78% from a negative CNY 41,762,078.34 in the previous year[21] - Cash received from sales and services increased by 50.36% to CNY 2,140,736,007.95 compared to CNY 1,423,717,455.42 in the same period last year[21] - Cash paid for operating activities surged by 460.40% to CNY 889,917,831.92, primarily due to foreign currency fund account transfers and repayments of bank loans[21] - Cash inflows from operating activities totaled CNY 2,803,503,432.46, an increase from CNY 1,499,829,767.20 year-over-year[39] - The net cash flow from operating activities was CNY 587,081,583.71, a significant improvement from a net outflow of CNY -41,762,078.34 in the same period last year[39] Assets and Liabilities - Total assets decreased by 6.80% to CNY 4,902,168,855.20 compared to the end of the previous year[7] - Net assets attributable to shareholders decreased by 9.82% to CNY 3,308,188,771.10 compared to the end of the previous year[7] - Cash and cash equivalents decreased by 39.33% to ¥1,164,348,251.48 from the beginning of the year, primarily due to the purchase of a 10% stake in Chengdu Rongsheng and repayment of bank loans[16] - The company's total liabilities decreased to CNY 627,279,849.36 from CNY 809,554,612.45, a reduction of 22.49%[25] - The company's equity increased to CNY 1,162,409,212.03, reflecting a growth in capital contributions and retained earnings[25] - Total assets as of September 30, 2018, were ¥2,246,236,821.49, down from ¥2,478,914,373.85 at the beginning of the year[28] - Total liabilities as of September 30, 2018, were ¥6,590,122.30, significantly reduced from ¥108,879,095.06 at the beginning of the year[28] Shareholder Information - The total number of shareholders reached 40,929 by the end of the reporting period[13] - The company completed a stock dividend distribution, increasing total shares from 670,106,928 to 871,139,006[9] Investment and Expenses - The company reported a significant reduction in financial expenses by 112.35%, reflecting improved cash flow post-restructuring[18] - The company’s capital reserve decreased by 70.59% to ¥259,414,220.95, primarily due to the acquisition of a 10% stake in Chengdu Rongsheng[17] - The management expenses for Q3 2018 were 7,108,836.37 RMB, compared to 2,487,638.92 RMB in Q3 2017, showing an increase of approximately 185%[35] - The financial expenses for Q3 2018 were -5,405,480.62 RMB, compared to -2,033,072.43 RMB in the same period last year, indicating a worsening of financial costs[35] Inventory and Receivables - Accounts receivable increased by 39.34% to ¥423,725,424.26, mainly due to the receipt of customer bills[16] - Prepayments rose by 79.64% to ¥42,531,450.84, primarily for advance payments for plasma and other raw materials[16] - Inventory increased to CNY 1,739,567,544.73, up from CNY 1,582,080,153.58, indicating a growth of 9.95%[24] Other Financial Metrics - Non-recurring gains and losses amounted to a net loss of CNY 402,830.19 for the period[12] - The weighted average return on equity decreased by 19.77 percentage points to 10.42%[7] - The company's cash and cash equivalents at the end of the period were CNY 1,162,409,212.03, down 34.74% from CNY 1,781,220,380.02 in the previous year[22]

Financial Performance - Total operating revenue for the first three quarters of 2018 reached CNY 2,056.59 million, an increase of 27.68% compared to the previous year's adjusted figure of CNY 1,610.79 million[3] - Net profit attributable to shareholders of the listed company was CNY 396.60 million, a decrease of 60.39% from the previous year's adjusted figure of CNY 1,001.35 million[3] - Basic earnings per share decreased to CNY 0.46, down 60.39% from the previous year's adjusted figure of CNY 1.15[3] - The weighted average return on equity dropped to 10.42%, a decrease of 19.77 percentage points from the previous year's adjusted figure of 30.19%[3] - The company recorded a substantial decrease in operating profit and total profit due to the previous year's one-time investment gains of CNY 758 million from the sale of stakes in two subsidiaries[6] Blood Products Business - The net profit from blood products business was CNY 568.20 million, representing a 47.93% increase from the previous year's adjusted figure of CNY 384.10 million[6] - The company expects significant growth in blood products business performance due to increased marketing efforts and refined management practices[5] - The company has integrated three blood product companies into its consolidated financial statements following a major asset restructuring[4] Assets and Cautionary Notes - Total assets at the end of the reporting period were CNY 4,906.49 million, a decrease of 6.72% from the beginning of the period[3] - Investors are advised to be cautious as the reported financial data for the first three quarters of 2018 is preliminary and unaudited[7]

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 1,220,289,175.04, representing an increase of 18.17% compared to the same period last year[16]. - The net profit attributable to shareholders for the first half of 2018 was CNY 240,273,198.11, a decrease of 72.73% year-on-year[16]. - The basic earnings per share for the first half of 2018 was CNY 0.28, down 72.73% from CNY 1.01 in the same period last year[17]. - The company's blood products business achieved a revenue of 1,220.29 million CNY, representing a 55.87% increase compared to the same period last year[29]. - Net profit reached 343.36 million CNY, marking a 62.19% year-over-year growth[29]. - The net profit attributable to shareholders was 240.27 million CNY, reflecting a 69.40% increase compared to the previous year[29]. - The company reported a total net assets of CNY 3,151,865,739.23, a decrease of 14.08% from the previous year-end[16]. - The total assets of the company decreased by 11.20% to CNY 4,670,840,704.49 compared to the end of the previous year[16]. - The total assets increased by 43.49% due to the consolidation of subsidiaries, including Wuhan Blood Products, Lanzhou Blood Products, and Shanghai Blood Products[35]. Cash Flow and Investments - The company's net cash flow from operating activities was CNY 333,631,453.65, showing a significant improvement from a negative cash flow in the previous year[16]. - Operating cash flow increased due to higher sales collections from the blood products business[46]. - The company reported a significant reduction in financial expenses, achieving a negative financial expense of ¥2,376,905.88 compared to a positive expense of ¥36,511,936.47 in the previous period, indicating a 106.51% improvement[50]. - Cash outflow from investment activities totaled ¥1,101,867,769.00, compared to ¥400,000,000.00 in the previous period, indicating a substantial increase in investment spending[138]. - The company received cash from the disposal of subsidiaries and other operating units amounting to ¥1,684,346,486.21[135]. Asset Management - The total assets at the end of the current period were ¥1,050,331,221.25, down 39.49% from ¥1,735,819,015.69 in the previous period[51]. - Current assets decreased from CNY 3,845,942,066.91 to CNY 3,206,569,755.51, a reduction of about 16.6%[122]. - Cash and cash equivalents dropped significantly from CNY 1,918,993,782.14 to CNY 1,050,331,221.25, a decrease of approximately 45.4%[122]. - Total liabilities decreased from CNY 809,554,612.45 to CNY 620,004,358.23, a decline of approximately 23.4%[124]. - The company reported a significant increase in accounts receivable from CNY 5,557,873.75 to CNY 14,009,138.14, an increase of about 151.5%[122]. Business Operations - The main business involves the development and production of blood products using healthy human plasma and recombinant technology, including products like albumin and immunoglobulin[23]. - Key products include human albumin, intravenous immunoglobulin, rabies immunoglobulin, and hepatitis B immunoglobulin, which are used for various medical treatments[24][25]. - The company operates under a procurement model that includes a network of plasma collection stations, ensuring compliance with national regulations and quality management systems[27]. - The production process involves strict quality control and testing of plasma to meet the standards set by the Chinese Pharmacopoeia[28]. - The company operates 56 plasma collection stations, with 47 currently in operation and 9 newly approved, covering 13 provinces in China[33]. Research and Development - The research and development strategy focuses on centralized R&D and decentralized registration, optimizing resource use and reducing redundant investments[28]. - Significant progress was made in R&D, with clinical approval obtained for recombinant human coagulation factor VIII[43]. - The company has a strong competitive edge due to its advanced production technology and a robust research and development team[37]. Regulatory Compliance and Governance - The company completed a major asset restructuring in January 2018, incorporating several subsidiaries into its consolidated financial statements[18]. - The company has established a commitment to resolve any competitive issues with its controlling shareholder post-restructuring[66]. - The company has committed to avoiding any business that competes with its main operations, effective since February 20, 2017[66]. - The company has undertaken to compensate Tian Tan Biological for any losses incurred due to violations of commitments made by China Biologic[70]. Environmental Responsibility - The company has been recognized as a key pollutant discharge unit by the Sichuan Provincial Environmental Protection Department, with specific wastewater and air emission standards being monitored[91]. - The company has established an emergency response plan for environmental pollution incidents, ensuring rapid and effective handling of such events[96]. - Chengdu Rongsheng processed a total of 133,491 m³ of wastewater during the reporting period, with an average daily treatment of 737.52 m³/d, achieving stable discharge standards without any exceedance incidents[93]. Shareholder Information - The total share capital increased from 670,106,928 shares to 871,139,006 shares following a stock dividend distribution[18]. - The cash dividend distributed was 2 RMB per 10 shares, totaling 134,021,385.60 RMB (including tax)[112]. - The largest shareholder, China Biotechnology Co., Ltd., holds 49.96% of the shares, totaling 435,233,646 shares[114]. - The company has a total of 43,137 common stock shareholders as of the end of the reporting period[113]. Risk Factors - The company faces risks related to national policy changes, product safety, and raw material supply, which could impact its operations and profitability[56][59]. - The blood product industry is subject to price fluctuations due to market supply and demand, which may affect the company's revenue[61].

Financial Performance - Total operating revenue for the first half of 2018 was CNY 122,028.92 million, an increase of 18.17% compared to CNY 103,264.35 million in the previous year[3] - Net profit attributable to shareholders of the listed company decreased by 72.63% to CNY 24,117.14 million from CNY 88,104.03 million in the same period last year[3] - Operating profit fell by 59.83% to CNY 41,790.70 million, down from CNY 104,027.69 million year-on-year[3] - Basic earnings per share decreased to CNY 0.28 from CNY 1.01, reflecting a decline of 72.63%[3] - The weighted average return on net assets dropped to 6.40%, down 20.30 percentage points from 26.70%[3] Assets and Liabilities - Total assets at the end of the reporting period were CNY 467,079.26 million, a decrease of 11.20% from CNY 525,996.81 million at the beginning of the period[3] Business Segments - The net profit from blood products business increased by 70.04% to CNY 24,117.14 million compared to CNY 14,183.62 million in the previous year[7] - The company expects significant profit increases from the blood products business due to improved production and sales after the integration of three blood product companies[5] One-time Events - The company reported a substantial decrease in operating profit and net profit due to the previous year's one-time investment gains of CNY 758 million from the sale of stakes in two companies[5] Cautionary Notes - The financial data for the first half of 2018 is preliminary and has not been audited, highlighting the need for caution among investors[6]

Financial Performance - In 2017, the company's operating income was CNY 1,765,169,679.35, a decrease of 17.45% compared to the previous year[19]. - The net profit attributable to shareholders was CNY 1,179,942,696.05, reflecting a decrease of 7.95% year-on-year[19]. - The total assets at the end of 2017 amounted to CNY 3,665,745,448.35, a decrease of 39.04% compared to the previous year[20]. - The company's net cash flow from operating activities was CNY 218,389,433.22, down 49.56% from the previous year[20]. - Basic earnings per share (EPS) increased to CNY 1.76 in 2017, a 359.33% increase compared to CNY 0.38 in 2016[21]. - The weighted average return on equity (ROE) rose to 41.52% in 2017, up from 11.56% in 2016, marking a 29.96 percentage point increase[21]. - The company reported a total revenue of CNY 467,058,854.14 in the fourth quarter of 2017[23]. - Blood products business revenue reached 151,379.83 million RMB, growing by 17.01% compared to the previous year (unadjusted) and 13.22% (adjusted) year-on-year[60]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2017, representing a growth of 15% compared to the previous year[191]. Dividend and Share Capital - The company plans to distribute a cash dividend of CNY 2 per 10 shares, totaling CNY 134,021,385.60, and issue 3 bonus shares for every 10 shares held[5]. - The total share capital will increase to 670,106,928 shares after the proposed stock distribution[132]. - For the 2017 fiscal year, the proposed cash dividend is 2 RMB per 10 shares, amounting to 134,021,385.60 RMB, with an additional 3 shares distributed for every 10 shares held[133]. Asset Management and Restructuring - The company completed two major asset restructuring projects in 2017, becoming the sole blood product business platform under China Biologic[29]. - The company completed significant asset restructuring, transferring 100% equity of subsidiary Beishengyan and 51% equity of Changchun Qijian, resolving competition issues with the controlling shareholder[61]. - The company has undergone significant asset transfers, including the transfer of subsidiaries, impacting various financial metrics[86]. Market and Product Development - The company is engaged in the research and development of blood products using recombinant technology, focusing on health human plasma as raw material[29]. - The company aims to enhance the comprehensive utilization rate of plasma and develop new products by upgrading production equipment and adopting new protein separation and purification technologies[51]. - The company is focusing on the development of blood products and recombinant factor products, aiming to improve plasma utilization through technology upgrades[97]. - New product development efforts are underway, with three new vaccines expected to be launched by Q3 2018, targeting a market size of 500 million[191]. Regulatory Environment - The company operates under strict regulatory oversight, requiring compliance with national standards for blood plasma collection and production, ensuring safety and quality[39]. - The blood products industry has high policy barriers due to strict regulations on plasma collection and production, requiring licenses and limiting the number of collection stations[42]. - Since 2001, the government has not approved new blood product manufacturing enterprises, maintaining strict total control over the number of companies in the industry[43]. Social Responsibility and Environmental Impact - The company donated RMB 600,000 to the Sichuan Medical Charity Fund to support poverty alleviation efforts, aiming to ensure health services for impoverished communities[162]. - The company has been actively involved in social responsibility initiatives, as detailed in its 2017 Social Responsibility Report[166]. - Chengdu Rongsheng's wastewater discharge for COD was 11.07 tons, with a concentration of 40.77 mg/L, well below the regulatory limit of 500 mg/L[167]. - The company established an ISO14001 environmental management system to effectively manage and reduce pollutant emissions[169]. Strategic Acquisitions and Partnerships - The company is actively pursuing strategic acquisitions to enhance its operational capabilities and market reach[155]. - The company completed a major asset restructuring project by acquiring 100% equity of Shanghai Blood Products, Wuhan Blood Products, and Lanzhou Blood Products in January 2018[156]. - The company acquired 80% equity in Guizhou Zhongtai for 36,080 million from China Biologic, enhancing its market position in the vaccine sector[155]. Executive Compensation and Governance - The company has a comprehensive executive compensation plan established by the board's performance assessment and compensation committee, which includes performance evaluations and salary adjustments based on annual assessments[198]. - The board of directors has undergone changes, with new independent directors and a general manager being elected, while some members have left due to work changes or term completion[199].